Thermo Fisher Scientific Inc. $TMO Shares Bought by Capital International Investors

Key Points

• Capital International Investors increased its Thermo Fisher Scientific stake by 0.6% in the fourth quarter, ending with 920,143 shares valued at about $533.2 million.
• Thermo Fisher reported better-than-expected quarterly results, with EPS of $5.44 versus $5.25 expected and revenue of $11.01 billion versus $10.86 billion expected; revenue rose 6.2% year over year.
• Analyst sentiment remains generally positive, with a Moderate Buy consensus and an average price target of $613.67, even though several firms recently lowered their targets.

Capital International Investors lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 920,143 shares of the medical research company's stock after purchasing an additional 5,136 shares during the quarter. Capital International Investors owned about 0.24% of Thermo Fisher Scientific worth $533,179,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Assetmark Inc. grew its position in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company's stock valued at $21,819,000 after acquiring an additional 7,023 shares during the period. Cornerstone Investment Partners LLC purchased a new stake in Thermo Fisher Scientific during the third quarter valued at about $41,393,000. Mackenzie Financial Corp grew its position in Thermo Fisher Scientific by 29.4% during the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company's stock valued at $134,130,000 after acquiring an additional 62,790 shares during the period. NEOS Investment Management LLC grew its position in Thermo Fisher Scientific by 28.6% during the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company's stock valued at $24,913,000 after acquiring an additional 11,415 shares during the period. Finally, Factory Mutual Insurance Co. grew its position in Thermo Fisher Scientific by 2.6% during the third quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company's stock valued at $47,985,000 after acquiring an additional 2,500 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TMO. Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a research report on Friday, April 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Jefferies Financial Group raised Thermo Fisher Scientific to a "strong-buy" rating in a research report on Friday, April 24th. Finally, Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the stock a "sector perform" rating in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $613.67.

Thermo Fisher Scientific Trading Up 0.0%

NYSE:TMO opened at $472.98 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The business's 50-day simple moving average is $479.94 and its 200 day simple moving average is $530.83. The stock has a market cap of $175.77 billion, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same quarter in the previous year, the firm posted $5.15 earnings per share. The company's revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.